What to do if ovarian cancer recurs after surgery

Ovarian cancer is a highly malignant gynecological tumor and is prone to widespread metastasis in the abdominal and pelvic cavities. Moreover, 80% of patients with advanced ovarian cancer will have recurrence during treatment. Although it is not as dangerous as the first time, it is also more difficult to treat. The symptoms of ovarian cancer recurrence mainly include lower abdominal drooping, discomfort, increased abdominal circumference, abdominal mass, enlarged abdomen, or menstrual disorders.

In response to the problem of postoperative recurrence and metastasis, an authoritative tumor biological treatment expert in the tumor field introduced that the cause of recurrence of recurrent ovarian malignant tumors is related to genetics, internal and external environment, and treatment methods. The incidence of ovarian cancer ranks third among gynecological tumors, but its mortality rate ranks first. Because ovarian epithelial cancer is already in the late stage when diagnosed, standardized treatment, that is, ideal tumor cell reduction surgery and combined chemotherapy with platinum or paclitaxel, has greatly improved the prognosis of some ovarian cancer patients. The key to treating tumors is to mobilize the body's immune function, and cell immunotherapy based on this principle has been multiplied in clinical applications and is regarded as the fourth treatment method after surgery, radiotherapy, and chemotherapy, which means that cancer patients have new treatment options.

Chemotherapy and radiotherapy are the most basic and important means of treating tumors. Through standardized and effective chemotherapy and radiotherapy, tumor cells can be killed to varying degrees and tumor load can be reduced to the greatest extent. However, chemotherapy and radiotherapy only selectively kill certain tumors, and their toxic side effects increase with increasing doses. Assisted by immunotherapy, on the one hand, it can kill residual cancer cells in the body and prevent tumor recurrence, and at the same time, it can improve the body's immunity, increase compliance with chemotherapy and radiotherapy, and prolong the patient's disease-free survival period.

At present, the conventional culture technology of CIK cells, DC cells or DC-CIK cells is to first use a blood cell separator to circulate 4000-8000 ml of peripheral blood of patients in vitro, extract the mononuclear cells in the peripheral blood, and then culture the cells in the GMP laboratory to obtain CIK, DC or DC-CIK immune cells with anti-cancer activity. In addition to surgery, chemotherapy and radiotherapy, which are the three conventional treatment methods for tumors, DC-CIK biological treatment is gradually entering people's field of vision as the fourth means of treating tumors. DC-CIK biological immunotherapy refers to a treatment method that uses various effective methods to assist or stimulate the body's own immune system to inhibit or kill tumor cells and resist cancer. Modern tumor immunity is the product of the trinity of traditional tumor immunity, modern immunology and biological high technology, and aims to establish a more effective and specific anti-tumor immune ability of the human body.